Gilead Sciences Balance Sheet Health
Financial Health criteria checks 2/6
Gilead Sciences has a total shareholder equity of $17.5B and total debt of $25.8B, which brings its debt-to-equity ratio to 147.9%. Its total assets and total liabilities are $56.3B and $38.8B respectively. Gilead Sciences's EBIT is $10.1B making its interest coverage ratio 17. It has cash and short-term investments of $4.7B.
Key information
147.9%
Debt to equity ratio
US$25.82b
Debt
Interest coverage ratio | 17x |
Cash | US$4.72b |
Equity | US$17.46b |
Total liabilities | US$38.84b |
Total assets | US$56.29b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($12.8B) do not cover its short term liabilities ($13.0B).
Long Term Liabilities: GILD's short term assets ($12.8B) do not cover its long term liabilities ($25.8B).
Debt to Equity History and Analysis
Debt Level: GILD's net debt to equity ratio (120.9%) is considered high.
Reducing Debt: GILD's debt to equity ratio has increased from 120.3% to 147.9% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (32.8%).
Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (17x coverage).